
April 17 (Reuters) - Nurix Therapeutics Inc NRIX.O:
NURIX ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR GS-6791/NX-0479 - A NOVEL IRAK4 DEGRADER FOR INFLAMMATORY CONDITIONS
NURIX THERAPEUTICS INC - GILEAD TO BEGIN PHASE 1 STUDY IN Q2 2025
NURIX THERAPEUTICS INC - TO RECEIVE $5 MILLION MILESTONE PAYMENT FROM GILEAD
NURIX THERAPEUTICS INC - ELIGIBLE FOR $420 MILLION IN FUTURE MILESTONES